

# The Importance of Local Anesthetics in Medical Practice and the Analysis of Side Effects Associated With their Use

Iroda Takhirova Brodarovna <sup>1</sup>

Sokhib Rashidov Zamon o'g'li <sup>2</sup>

**Abstract:** By quickly and effectively relieving pain and other clinical problems while reducing recovery time, the use of low-dose local anesthetics (LAs) has dramatically improved patient care. In order to prioritize future research, this study intends to identify gaps in the present literature and describe the scientific data currently available on the therapeutic use of low-dose LAs in a variety of illnesses. The five separate steps of the Arksey and O'Malley framework's methodological principles were followed in this systematic scoping review. In dentistry and medical practice, local anesthetics have a remarkable track record of safety and effectiveness. It makes sense for physicians to ignore many of their pharmacotherapeutic principles because their use is so common and side effects are so rare. This continuing education article's goal is to examine and update the fundamental pharmacology of the many local anesthetic formulations that are currently in use. In a later essay, technical aspects will be discussed. Furthermore, indicators unrelated to pain were found (13.95%). Overall, the administration of short-acting, low-dose LAs showed significant results in terms of pain management and a decrease in anxiety and depression ratings, improving the patients' quality of life. In terms of the therapeutic role of LAs, this review is the first systematic scoping review. Further rigorous research, including bigger, well-designed randomized controlled trials (RCTs) and long-term outcome monitoring, is necessary to validate the claimed positive impacts on safety and efficacy.

**Keywords:** Dentistry, pharmacology, drug toxicity, local anesthetics, procaine, lidocaine, neurological treatment, pain.

---

<sup>1,2</sup> Department of Pharmacology of the Tashkent State Medical University

---

**Introduction.** Local anesthetics (LAs) have been used therapeutically since the Austrian ophthalmologist Carl Koller used cocaine's anesthetic qualities to perform the first surgery in 1894. Einhorn created the local anesthetic procaine in 1905. A year later, Spiess reported that procaine injections quickly reduced inflammation, which he attributed to the drug's influence on the nervous system. LAs, also known as neural treatment (NT) or therapeutic local anesthesia, are widely used for therapeutic purposes in Europe

as a result of the medical profession building on the groundbreaking concepts of the Huneke brothers and others over time. By preventing sodium ions from entering neuronal membranes through channels or ionophores, local anesthetics stop neural conduction. These channels are typically in a resting state, which prevents sodium ions from entering. The channel becomes activated or open when the neuron is stimulated, allowing sodium ions to permeate the cell and start depolarization [1,2,3]. The sodium channel enters an inactivated state after this abrupt shift in membrane voltage, which prevents additional input while active transport mechanisms return sodium ions to the outside. The channel returns to its typical resting state after this repolarization. The selective sensitivity of local anesthetics for different kinds of neuronal fibers can be explained by an understanding of these sodium channel states. When local anesthetics are in their active and inactivated stages, they have a higher affinity for sodium channel receptors than when they are at rest. As a result, neural fibers that fire more quickly are more vulnerable to the effects of local anesthetics. Additionally, because a given volume of local anesthetic solution can more easily block the necessary number of sodium channels for impulse transmission to be completely disrupted, smaller fibers are typically more vulnerable. Because of these factors, the most sensitive fibers are the small, fast-firing autonomic fibers, which are followed by sensory fibers and somatic motor fibers [4,5,6,7]. These differences in sensitivity are well known to the anesthesiologist who blocks mixed spinal nerves. After recovering from spinal anesthesia, individuals can micturate (autonomic control) after regaining voluntary motor function and feeling. Since only tiny, fast-firing sensory fibers make up the trigeminal nerve branches that are anesthetized for dental treatments, the dentist is typically exempt from this issue. The sizes and firing rates of the various kinds of sensory fibers, however, also differ. Pain fibers, for instance, are more sensitive than proprioceptive and pressure fibers. Even after pain fibers are completely anesthetized, a patient may still experience pressure. Nevertheless, a thorough grasp of the breadth and methodology of these investigations is lacking. In addition to identifying gaps in the literature to direct future research, this review aims to summarize and characterize the present scientific data on therapeutic LAs for pain treatment and other disorders [8,9,10,11].

**The main purpose** of this brief review is to analyze the importance of local anesthetics in medical practice and the side effects associated with their use, based on the results of reputable scientific research.

**The general characteristics of local aesthetics.** Three elements make up the molecular structure of all local anesthetics: (a) lipophilic aromatic ring, (b) intermediate ester or amide bond, and (c) tertiary amine. Each of these elements gives the molecule unique clinical characteristics. **Anesthetic Strength.** The potency of local anesthetics varies, enabling amounts that usually fall between 0.5 and 4%. This is mostly due to variations in lipid solubility, which promotes diffusion through neural membranes and nerve sheaths. The aromatic ring and its substitutions, as well as those added to the tertiary amine, determine this feature. For instance, bupivacaine can be prepared as a 0.5% concentration (5 mg/mL) instead of a 4% concentration (40 mg/mL) because it is more potent and lipid soluble than articaine [3-8]. **Onset Time.** A drug's efficacy is increased and it can diffuse across cell membranes more quickly when it is more lipid soluble. This accelerates the onset of anesthesia in isolated fibers during in vitro experiments for local anesthetics, but it is important to recognize that additional variables are involved in clinical settings. Before the anesthetic reaches the neuronal membrane, for instance, intrinsic vasodilating qualities may encourage systemic absorption. High lipid solubility promotes sequestration in nearby adipose tissues or myelin sheaths and may hinder dispersion throughout tissue fluids. In either scenario, the beginning is delayed and fewer molecules reach the neural membrane [9-12]. Therefore, in contrast to in vitro studies of isolated fibers, higher lipid solubility generally slows the onset of anesthesia in the clinical setting; however, this influence can be countered by injecting higher concentrations that allow a greater number of molecules to reach the membrane and hasten onset. While both bupivacaine and articaine are highly lipid soluble, the 4% concentration of articaine provides for a much faster onset. The proportion of these molecules that exist in a lipid-soluble state as opposed to a water-soluble state. The terminal amine shown in Figure 1 can exist as a positively charged quaternary form (four bonds) that makes the molecule water soluble or as a tertiary form (three bonds) that is lipid soluble. The local anesthetic base is prepared as a hydrochloride salt in order for it to remain stable in solution. Because of

this, when the molecules are injected, they are in a quaternary, water-soluble condition and cannot enter the neuron. Consequently, the percentage of molecules that change to the tertiary, lipid-soluble structure when exposed to physiologic pH (7.4) directly affects the time it takes for local anesthetic to start [13-16].

**Elimination and Metabolism.** The intermediate chain or linkage establishes the pattern of elimination of local anesthetics and offers a practical basis for their classification. While the liver biotransforms amides, plasma esterases hydrolyze esters in the bloodstream. Except for benzocaine, which is present in a number of topical anesthetic preparations, ester local anesthetics are rarely utilized and are no longer marketed in dental cartridges. In this sense, Articaine is distinct. Despite having an ester side chain on its aromatic ring, it is categorized as an amide based on its intermediate linkage. This side chain's hydrolysis makes the molecule inactive, and as a result, it is removed in the same way as ester anesthetics [1,4,5].

**Length of Action.** The duration of action of local anesthetics varies, mostly because of variations in their affinity for proteins. Local anesthetics bind to plasma proteins reversibly while in circulation, just like the majority of medications. An anesthetic's affinity for protein within sodium channels has also been discovered to be correlated with this feature, which is quantified as the percentage of circulating medication that is protein bound. The longer the anesthetic maintains neuronal blockage, the higher the propensity for protein binding. For instance, the difference in the length of neural blockage between bupivacaine and mepivacaine is attributed to the former's 95% protein binding and the latter's 55%. Duration of anesthesia is also influenced by the time a local anesthetic remains in close proximity to neural fibers [7,8,9]. Sequestration of highly lipid-soluble anesthetics locally may allow for continual release to the neuronal membranes, prolonging duration, but constriction of neighboring vasculature is more significant in this regard. For this reason, vasopressors are added to many formulations in order to delay absorption and prolong anesthesia. This is particularly important because local anesthetics themselves vary in their ability to produce vasodilation. For example, when used without vasopressors, lidocaine shortens its own duration by dilating local vasculature, whereas mepivacaine and bupivacaine do not. Plain lidocaine formulations may be useful for brief procedures following infiltration, but their efficacy for nerve block is poor [6,9,10].

**Anesthetic toxicity in the location.** Local anesthetic-related systemic toxicity is dosage dependant, however it's not always easy to understand these levels. Unfortunately, the usage of anesthetic cartridges in dentistry has led to a lack of awareness regarding the precise amount of anesthetic we give our patients. Unfortunately, undergraduate education and other reputable dental periodicals continue to promote this practice. Instead of a dose, which is better described as milligrams or micrograms, a dental cartridge represents a volume. Additionally, dental cartridges frequently include two medications, each with a different dosage: a vasopressor and a local anesthetic. Dental cartridges include odd capacities like 1.7 or 1.8 mL, which further complicates things. The combination of these problems makes genuine dosage calculations difficult and encourages memorization of cartridge numbers rather than true understanding of appropriate dosages. Cartridges with different amounts of local anesthetics and vasopressors complicate this procedure even further. It is advisable to abandon the idea of cartridges and assume that each one has a volume of 2 mL in order to make dosage calculations easier. This is a safe method of overestimating the amount given to a patient [5-11]. For instance, anticipate it to be 9 mL after administering 4½ cartridges. The peripheral nervous system and central nervous system (CNS) are depressed in a dose-dependent manner as local anesthetics are absorbed from the injection site, increasing their concentration in the bloodstream. Ironically, greater concentrations cause seizures, whereas low serum concentrations are employed clinically to decrease cardiac arrhythmias and status seizures. The first potentially fatal effect of a local anesthetic overdose is convulsive seizures. This is probably because central inhibitory pathways are selectively depressed, allowing excitatory tracts to run wild. All pathways are blocked when serum concentrations climb further, leading to unconsciousness, respiratory arrest, and ultimately cardiovascular collapse. Although convulsive seizures often require concentrations >10 µg/mL, evidence of lidocaine toxicity may start at concentrations >5 µg/mL [12-16].

**Local anesthetic allergy.** Patients frequently claim to be allergic to local anesthetics. However, upon close examination, one typically discovers that what they experienced was either a syncopal episode linked to the injection or heart palpitations caused by either endogenously released or solution-containing epinephrine. Preservatives (methylparaben) or antioxidants (sulfites) in the solution are more likely to cause allergic responses after local anesthetic injections. Multidose vials contain methylparaben to stop microbiological development. Dental cartridges and single-dose vials no longer contain it. Only dental cartridges containing levonordefrin or epinephrine contain sulfites, which stop vasopressors from oxidizing. Immune systems cause allergic reactions by sensitizing cells to antigens, which then mediate a number of pathophysiologic alterations following recurrent exposure. Based on different immunologic pathways, Gell and Coombs initially classified hypersensitivity (allergic) reactions as Type I through IV. Type I reactions, which are mediated by antibodies or immunoglobulin E (IgE) generated by B cells, happen minutes after provocation [6-10]. This is the kind that local anesthetic formulation ingredients most frequently cause. Sensitized T cells mediate type 4 reactions, which take many days to manifest after provocation. Rarely has this kind of response to local anesthetics been linked. The dentist should refrain from employing the offending agent until an allergist has assessed the patient if the patient reports a reaction that is at least clinically consistent with allergy. Mepivacaine or prilocaine without vasopressors would be the best options if an anesthetic is needed prior to receiving medical clearance. According to conventional belief, esters of PABA are more likely than amide local anesthetics to cause allergies if local anesthetics do. Additionally, one can avoid any bisulfites that are included as antioxidants by staying away from solutions that contain vasopressors. It is possible for persons with asthma or atopia to be sensitive to different sulfites [11-17].

**Dicussion.** An earlier continuing education article in this publication covered potential medication interactions in great detail. The most significant of these have to do with potential increased cardiovascular stimulation. The cardiotonic effects of vasopressors, which are present in local anesthetic formulations, may intensify when patients are taking other medications that have comparable effects. These include digoxin, thyroid hormone, tricyclic and monoamine oxidase inhibitor antidepressants, and any sympathomimetics used for attention deficit disorders or weight control. Although they are not contraindicated in these people, vasopressors should be used cautiously and in the way previously discussed for patients with medical conditions. It may be prudent to completely avoid vasopressors in patients who are suspected of abusing stimulant drugs, such as cocaine. Patients taking nonselective beta blockers are also recommended to utilize vasopressors with caution. Nonselective drugs also block vascular beta-2 receptors, in contrast to selective agents that solely block beta-1 receptors on the heart. Vasopressors' alpha agonist activity intensifies in this situation, potentially leading to dangerously high mean and diastolic arterial pressures. Usually, this is followed by an abrupt reflex heart rate slowing [1-6]. There is ample evidence of the significant effects of this interaction. The temporal course of the interaction with beta blockers is the same as that of typical cardiovascular reactions to adrenaline. It starts after absorption from the injection site, which usually peaks after 5 minutes and then decreases over the next 10 to 15 minutes. Patients on nonselective beta blockers are not contraindicated to use vasopressors; nevertheless, dosages should be cautious, and blood pressure should be periodically checked while the medication is being administered, as previously mentioned. Avoid using gingival retraction cords that have been impregnated with racemic epinephrine. The quantities of epinephrine in these medications are significantly higher than those in formulations for local anesthetics. Vasopressor maximum allowable dosages have not been determined. The duration of treatment can be as short as 30 minutes or as long as 3-4 hours; it is not realistic to describe limitations in terms of appointments. Additionally, the impact of a particular vasopressor dosage varies greatly among patients. Since both adrenaline and levonordefrin are catecholamines that are quickly metabolized by catechol-o-methyltransferase, peak effects of epinephrine are typically seen 5-10 minutes after injection and immediately fade [7-12]. The majority of catecholamines actually have an elimination half-life of only one to three minutes. The hemodynamic effects often appear minutes after injection and totally go away in ten to fifteen minutes. The most cautious and often mentioned dose restriction for people with severe cardiovascular disease is 40 µg of

epinephrine (about two cartridges containing 1 : 100,000). It should be made clear that this recommendation more accurately represents 30-minute intervals rather than appointments. It makes more sense to base the dosage on patient evaluation rather than maximum dosages. For instance, it seems sense to measure the patient's baseline blood pressure and heart rate before surgery and again after every 20–40 µg if the patient's health is in doubt. This would be equivalent to one or two cartridges with a concentration of one hundred thousand epinephrine. The cardiovascular effects of this quantity can be tolerated by almost any patient. Additional doses and a similar sequence of reevaluating vital signs may be given if the patient stays stable [13-18].

**Conclusions.** In conclusion, our comprehensive scoping review demonstrates the therapeutic potential of LAs in a range of clinical settings with established mechanisms of action. With no notable side effects, LAs have continuously shown safety and effectiveness in the treatment of pain, inflammation, and other ailments and associated symptoms when used responsibly. To further understand pathophysiologic mechanisms and discover novel therapeutic approaches, more thorough research is required. Determining the ideal dosage, improving treatment approaches, and assessing long-term results should be the top priorities for future study.

Finally, it should be noted that the action of vasopressors on submucosal arteries has been successfully reversed by the introduction of a local anesthetic reversal agent. Dental cartridges include phentolamine (OraVerse), an alpha receptor blocker. The duration of anesthesia is shortened when it is injected into the same location as the anesthetic was given because vessels dilate and the local anesthetic is better absorbed.

Due to its high cost and the fact that persistent anesthesia usually helps with pain control throughout the postoperative phase, its usage is probably going to be restricted. While tissues are still numb, it might be helpful in the treatment of young children or individuals with specific needs who might be more vulnerable to self-inflicted harm. The old or weak diabetic patient, whose extended numbness may make it difficult for them to consume enough nutrients, may also be taken into account. The busy patient who has to go back to work and communicate well may also be offered reversal.

## References.

1. Taylor, A. et al. Basic pharmacology of local anaesthetics. *BJA Education*, 2020, Volume 20, Issue 2, 34 – 41.
2. Becker DE, Reed KL. Local anesthetics: review of pharmacological considerations. *Anesth Prog.* 2012 Summer;59(2):90-101; quiz 102-3. doi: 10.2344/0003-3006-59.2.90.
3. Weinschenk, S. Neural therapy-Areview of the therapeutic use of local anesthetics. *Acupunct. Relat. Ther.* 2012, 1, 5–9. Pavlov, V.A.; Chavan, S.S.; Tracey, K.J. Molecular and Functional Neuroscience in Immunity. *Annu. Rev. Immunol.* 2018, 36, 783–812.
4. Fischer, L.; Barop, H.; Ludin, S.M.; Schaible, H.G. Regulation of acute reflectory hyperinflammation in viral and other diseases by means of stellate ganglion block. A conceptual view with a focus on COVID-19. *Auton. Neurosci.* 2022, 237, 102903.
5. Fischer, L.; Barop, H.; Ludin, S.M.; Schaible, H.G. Regulation of acute reflectory hyperinflammation in viral and other diseases by means of stellate ganglion block. A conceptual view with a focus on COVID-19. *Auton. Neurosci.* 2022, 237, 102903.
6. Fleckenstein, J.; Neuberger, E.W.I.; Bormuth, P.; Comes, F.; Schneider, A.; Banzer, W.; Fischer, L.; Simon, P. Investigation of the Sympathetic Regulation in Delayed Onset Muscle Soreness: Results of an RCT. *Front. Physiol.* 2021, 12, 697335.
7. Puente de la Vega, K.; Gómez, M.; Roqueta, C.; Fischer, L. Effects on hemodynamic variables and echocardiographic parameters after stellate ganglion block in 15 healthy volunteers. *Auton. Neurosci.* 2016, 197, 46–55.

8. Shiratori Tusita, L.N.; Fischer, L. Chronic Therapy-Resistant Neck Pain in a Fifty-Year-Old Man: The Role of Partially Impacted Third Molars—Case Report and New Pathophysiological Insights. *Complement. Med. Res.* 2023, 30, 270–274.
9. Lopes, C.A.; Fischer, L. A case of severe trigeminal neuralgia: Recovery by means of stellate ganglion block with procaine. Discussion of possible mechanisms of action. *J. Int. Med. Res.* 2023, 51, 3000605231164479.
10. Vinyes, D.; Muñoz-Sellart, M.; Caballero, T.G. Local anesthetics as a therapeutic tool for post COVID-19 patients: A case report. *Medicine* 2022, 101, e29358.
11. Rey, M.; Muñoz, M.; Catalán, M.; Vinyes, D. Treatment of Localized Vulvar Pain with Neural Therapy: A Case Series and Literature Review. *Complement. Med. Res.* 2021, 28, 571–577.
12. Bashan, I.; Ozturk, G.Y. Effect of Neural Therapy on shoulder dysfunction and pain in supraspinatus tendinopathy. *Pak. J. Med. Sci.* 2022, 38 Pt I, 565–569.
13. Feigin, G.; Velasco Figueroa, S.; Englesakis, M.F.; D’Souza, R.; Hoydonckx, Y.; Bhatia, A. Stellate Ganglion Block for Non-Pain Indications: A Scoping Review. *Pain Med.* 2023, 2, pna011.
14. Rahimzadeh, P.; Mahmoudi, K.; Khodaverdi, M. Faiz SHR: Effects of ultrasound guided ganglion stellate blockade on intraoperative and postoperative hemodynamic responses in laparoscopic gynecologic surgery. *Videosurgery Miniinv* 2020, 15, 351–357.
15. Tepe, N.; Tertemiz, O.F. Comparison of greater occipital nerve and greater occipital nerve + supraorbital nerve block effect in chronic medication overuse headache. *Turk. J. Med. Sci.* 2021, 51, 1065–1070.
16. Gradinaru, D.; Ungurianu Am Margina, D.; Villanueva, M.M.; Bürkle, A. Procaine-The Controversial Geroprotector Candidate: New Insights Regarding its Molecular and Cellular Effects. *Oxid. Med. Cell. Longev.* 2021, 2021, 3617042.
17. Vinyes D, Muñoz-Sellart M, Fischer L. Therapeutic Use of Low-Dose Local Anesthetics in Pain, Inflammation, and Other Clinical Conditions: A Systematic Scoping Review. *Journal of Clinical Medicine.* 2023; 12(23):7221. <https://doi.org/10.3390/jcm12237221>
18. Kirkpatrick, K.; Khan, M.H.; Deng, Y.; Shah, K.B. A review of Stellate Ganglion Block as an Adjunctive Treatment Modality. *Cureus* 2023, 15, e35174.